TFome™, the world’s first “plug-and-play” iPSC cellular programming platform, streamlines development and accelerates pipeline of potential best-in-class cell therapies across diverse therapeutic areas 

“Our technology allows us to discover novel cell-differentiation recipes and make practically any cell type in the body, including those that have not been made before,” said Alex Ng, co-first author with Parastoo Khoshakhlagh

GCTx founders co-authored with other distinguished US and international scientists "A comprehensive library of human transcription factors for cell fate engineering" published in the November 2020 issue of Nature Biotechnology

Harvard Medical School describes how GCTx is tackling COVID-19 utilizing our TFome cell engineering technology

Biogen awarded GCTx Golden Tickets, which provide lab space at Lab Central

CBS 60 Minutes featured our synthetic biology-based cell therapy platform technology

Amgen awarded GCTx Golden Tickets, which provide lab space at Lab Central (Cambridge, MA) and access to Amgen’s expertise in drug development

One year, 1 lab, 16 spinouts. Nature Biotechnology featured GCTx as a successful startup

YEi Start in France is an accelerator program for science-based startup companies

“The people who want to change the world are people who want to keep moving,” said Harvard President Lawrence Bacow during the ceremony

“The teams competing in this year’s President’s Innovation Challenge (PIC) represent the extraordinary talent that exists across the University,” said Harvard President Lawrence Bacow GCTx: Revolutionizing cell therapy by building a cell engineering platform that is 100 times faster and 10 times more efficient, enabling customized therapeutics tailored to target hard-to-cure diseases

Award recognizes TFome platform technology that enables rapid engineering of a broad spectrum of tissue-specific cell types